Product Description
Mechanisms of Action: PA Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Austria | Croatia | Iceland | Ireland | Latvia | Netherlands | Poland | Portugal | Romania | Switzerland
Approved Indications: None
Known Adverse Events: None
Company: Leiden University Medical Center
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Type 1 Diabetes|Arthritis, Rheumatoid|Hypertension
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
ASPIRETENSION II | P3 |
Active, not recruiting |
Hypertension |
2012-08-18 |
|
2007-004354-90 | P4 |
Active, not recruiting |
Unknown |
2008-03-03 |
|
ASPIRETENSION | P3 |
Active, not recruiting |
Type 1 Diabetes|Arthritis, Rheumatoid|Hypertension |
2006-11-02 |